Monoclonal B-cell lymphocytosis and prostate cancer: incidence and effects of radiotherapy.
Fiorella D'AuriaLuciana ValvanoLuciana RagoTeodora StatutoGiovanni CaliceGiovanni D'ArenaVincenzo FuscoPellegrino MustoPublished in: Journal of investigative medicine : the official publication of the American Federation for Clinical Research (2019)
Monoclonal B-cells lymphocytosis (MBL) is a benign condition that may precede chronic lymphocytic leukemia (CLL), not rarely present in peripheral blood of healthy elderly people, among which there is also a male prevalence. Though CLL has been associated with various types of solid tumors, including prostate cancer (PC), no data exist about the relationship between PC and MBL. We studied the frequency of CLL-like MBL clones in a group of 48 patients affected by PC and followed them during and after whole-pelvis radiotherapy (WPRT) treatment. We found four MBL clones (8.3%), two of which (4.2%) had a B-cell clonal count >1000 cells/µL ('clinical MBL'). A single case (1.8%) of 'low-count' MBL occurred in a control group of 54 healthy males. Notably, normal B-lymphocytes were consistently affected by WPRT, while MBL clones were less radiosensitive. Our results suggest a possible association between 'clinical' MBL and PC and show a different impact of the radiation on monoclonal respect to normal B-cells, which could also imply a greater risk of clonal transformation.
Keyphrases
- chronic lymphocytic leukemia
- prostate cancer
- peripheral blood
- early stage
- radical prostatectomy
- radiation therapy
- risk factors
- radiation induced
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- multiple myeloma
- locally advanced
- cell death
- chronic kidney disease
- signaling pathway
- prognostic factors
- electronic health record
- machine learning
- rectal cancer
- cell cycle arrest
- patient reported outcomes
- deep learning